News

€70m fund for EU biotechs
Enlarge image

BusinessEUGermanySwitzerlandUKAustria

€70m fund for EU biotechs

20.09.2012 - The European VC firm Wellington Partners has announced the first closing of a fund exclusively dedicated to investments in EU life sciences companies.

Money for life science companies is coming back to Europe. After Edmond de Rothschild Investment Partners scored €125m for its fourth life sciences fund and Index Ventures announced to put €150m into life sciences companies, now, Wellington Partners (London, Zurich, Munich) has attracted commitments of over  €70m  for its new Wellington Partners IV Life Science Fund. With a target size of €120m, the venture capitalists expect it to be significantly larger than the previous Wellington Partners III Life Science Fund, which raised €78m. Investments will focus on European companies developing innovative medical devices, diagostics and biotechnology.

According to Wellington’s investment team, the new fund attracted investors from Germany, Switzerland, Austria, Benelux, France, the UK, the US and the Middle East, among them the European Investment Fund (EIF), LfA Förderbank Bayern, Austria Wirtschaftsservice GmbH and certain large family offices.

Dr. Rainer Strohmenger, General Partner at Wellington Partners, said that the closing was a "big success in a challenging financial environment". For investors who are willing to act anti-cyclically, the sector would „provide the opportunity to generate outstanding returns.“

Wellington Partners’ portfolio already comprises some successful European life sciences players, amongst them Swiss Actelion or German mtm laboratories, which was swallowed by Roche last year for up to €190m. Other players include: Cancer vaccine developer immatics, medtech company Invendo Medical, diagnostics specialist Oxford Immunotec, and heart valve developer Symetis. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-03/wellington-partners-closes-eur70m-fund.html

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • EPIGENOMICS3.78 EUR11.83%
  • MOLOGEN7.75 EUR6.02%

FLOP

  • SANTHERA92.70 CHF-7.39%
  • MEDIGENE4.40 EUR-2.87%
  • ADDEX3.82 CHF-2.80%

TOP

  • SANTHERA92.70 CHF54.8%
  • EPIGENOMICS3.78 EUR18.1%
  • BB BIOTECH143.70 EUR11.1%

FLOP

  • WILEX2.40 EUR-11.1%
  • BIOFRONTERA2.40 EUR-10.4%
  • VITA 343.77 EUR-9.4%

TOP

  • SANTHERA92.70 CHF3965.8%
  • CO.DON2.45 EUR184.9%
  • PAION2.38 EUR158.7%

FLOP

  • CYTOS0.26 CHF-93.7%
  • MEDIGENE4.40 EUR-70.1%
  • MERCK KGAA66.43 EUR-42.9%

No liability assumed, Date: 01.09.2014